| Number of trials n = 71 (%) | Secondary Endpoint Discrepancy n = 45 (%) | P Value |
---|---|---|---|
Trial Initiation Period | |||
 1994–2005 | 30 (42) | 19 (42) | 0.9944 |
 2006–2010 | 41 (58) | 26 (58) |  |
Trial Result | |||
 Negative | 37 (52) | 26 (58) | 0.2087 |
 Positive | 34 (49) | 19 (42) |  |
Funding Source | |||
 Non-pharma | 33 (46) | 18 (40) | 0.1499 |
 Pharma | 38 (54) | 27 (60) |  |
Duration of Trial | |||
 < 3 years | 30 (42) | 21 (47) | 0.3220 |
 ≥ 3 years | 41 (58) | 24 (53) |  |
Number of clinical trial protocol non-primary endpointsa | |||
 ≤ 6 | 36 (51) | 19 (42) | 0.0600 |
 > 6 | 35 (49) | 26 (58) |  |
Protocol Lengtha | |||
 ≤ 34 pages | 36 (51) | 22 (49) | 0.4969 |
 > 34 pages | 35 (49) | 23 (51) |  |
Study Phaseb | |||
 II | 10 (14) | 7 (16) | 0.8984 |
 III | 57 (50) | 35 (78) |  |
Study Intervention | |||
 Systemic | 53 (75) | 37 (82) | 0.0536 |
 Non-systemic | 18 (25) | 8 (18) |  |
Protocol Type | |||
 Full | 60 (85) | 39 (87) | 0.5162 |
 Appended | 11 (15) | 6 (13) |  |